OSAKA, Japan and CAMBRIDGE, Mass. — September 22, 2026
Takeda announced that new data from its oncology pipeline and portfolio will be presented at the ESMO Congress 2026 in Madrid, Spain, including late-breaking Phase 3 data for investigational arcotatug tavatecan (TAK-921) and new findings for TAK-928. The company said the presentations will highlight its development programs in gastric cancer and non-small cell lung cancer (NSCLC) alongside clinical and real-world analyses of ALUNBRIG® (brigatinib) and FRUZAQLA® (fruquintinib). ESMO 2026 is scheduled for October 23-27.
Arcotatug Tavatecan Advances in Gastric Cancer
Late-breaking data from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan will be presented in previously treated advanced gastric or gastroesophageal junction adenocarcinoma. The study is being conducted in Japan and China and will be featured in the ESMO proffered paper session on October 23. Arcotatug tavatecan is an investigational Claudin 18.2-targeted antibody-drug conjugate (ADC) incorporating an exatecan payload and an Fc-silenced backbone designed to reduce Fc-mediated toxicities. Takeda said the final study results could support a potential regulatory filing in Japan, subject to evaluation of the data.
TAK-928 Program Expands Across NSCLC Settings
New data for TAK-928 will include studies evaluating the investigational therapy in immunotherapy-resistant NSCLC and previously untreated NSCLC. TAK-928 is described by Takeda as a potential first-in-class PD-1/alpha-biased IL-2 bispecific fusion protein. The company is conducting the global Phase 3 MarsLight-11 study (NCT07217301), evaluating TAK-928 against docetaxel monotherapy in patients with squamous NSCLC whose disease has progressed during or after chemotherapy and immunotherapy. Takeda also plans to add a new non-squamous NSCLC sub-trial to the MarsLight-11 program, expanding clinical evaluation across additional NSCLC populations.
Takeda Advances Broader Thoracic and GI Oncology Portfolio
Takeda’s ESMO 2026 program also includes clinical and real-world analyses of approved oncology medicines across thoracic and gastrointestinal cancers. An interim real-world analysis will examine treatment patterns and outcomes with ALUNBRIG as first-line therapy for adults with ALK-positive metastatic NSCLC, while updated results from the global FRUZAQLA Expanded Access Program will assess experience in patients with previously treated metastatic colorectal cancer. Takeda said its oncology strategy focuses on hematologic, thoracic and gastrointestinal cancers, with arcotatug tavatecan and TAK-928 representing investigational additions to its late-stage development portfolio. Neither investigational compound has been approved by the FDA or other regulatory authorities.
Source :Takeda, press release



